46brooklyn Research

What 46brooklyn Research does

46brooklyn Research is an Ohio-based 501(c)(3) public charity (EIN #83-3213092) founded in August 2018 by Eric Pachman and Antonio Ciaccia. The organization's stated purpose is to improve the accessibility and usability of U.S. drug pricing data by aggregating disparate public drug pricing sources scattered across government databases and stitching them into accessible interactive visualizations and original research. It serves the general public, payers and policymakers (including state Medicaid programs and Medicare Part D analysts), and healthcare journalists seeking to understand how the U.S. drug supply chain functions.

The core technology is a data aggregation and visualization platform that synthesizes public drug pricing sources — including CMS Medicare and Medicaid data, NADAC pharmacy acquisition cost data, and brand Wholesale Acquisition Cost (WAC) data — into a suite of interactive dashboards. Core products include the Medicare Part D Dashboard, NADAC Drug Pricing Dashboard, and Brand Drug List Price Change Box Score, supplemented by long-form original research publications analyzing PBM practices, rebate structures, and supply chain economics, plus a podcast, news section, Drug Channel Contracts Database, curated public data sources repository, and a Pharmacy Terms Glossary. Distribution is entirely free, self-serve, and global via the website with no registration or paywall.

The organization operates a donation-based revenue model through PayPal; no products or services are sold and no pricing tiers exist. It received 501(c)(3) tax-exempt status in August 2019, enabling tax-deductible contributions. Both co-founders have since departed — Eric Pachman (now associated with Bancreek) and Antonio Ciaccia — with operations continuing via a small team that includes research staff such as Ben Link, governed by a board of directors and volunteer staff structure. The organization reported no funding rounds, no acquisitions, no partnerships, and no revenue disclosures in the source materials.

Name

46brooklyn Research

Legal name

46brooklyn Research LLC

Website

https://46brooklyn.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

46brooklyn Research is an Ohio-based 501(c)(3) non-profit that aggregates and visualizes disparate U.S. drug pricing data sources into accessible dashboards and publishes original research on drug supply chain economics for the public, policymakers, and journalists.

Ownership category

akta.pro rank

Product category

Drug Pricing Research and Analytics

NAICS

Newspaper, Periodical, Book, and Directory Publishers (5131)

akta.pro primary industry

Government Pricing & Compliance (Medicare/Medicaid/340B/AMP/Best Price) (HLAIAKAE)

akta.pro secondary industries

Pricing Operations & Analytics (Price Governance, Systems, Reporting) (HLAIAKAK), 340B Program Administration & Contract Pharmacy Services (HLAFALAL)

Keywords

• Drug pricing research
• Pharmaceutical data analytics
• Healthcare cost transparency
• Prescription drug visualization
• PBM rebate analysis

Headquarters

HQ city

Bellbrook

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Donations and Charitable Contributions: 46brooklyn Research is a 501(c)(3) public charity (EIN #83-3213092). The organization accepts monetary donations through PayPal, which are tax-deductible to the fullest extent allowed by tax laws. No revenue-generating products or services are offered.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

46brooklyn Research aggregates disparate U.S. drug pricing data sources scattered across the web (CMS, Medicaid, Medicare Part D, NADAC, WAC) into interactive data visualizations and publishes original long-form research analyzing drug supply chain economics, PBM practices, and rebate structures. All outputs are provided to the public free of charge as part of its 501(c)(3) public charity mission.

Product overview

46brooklyn Research is an Ohio-based 501(c)(3) non-profit organization (EIN #83-3213092) focused on improving accessibility and usability of U.S. drug pricing data. The organization operates as a unified research and data visualization platform, combining multiple products: (1) Data Visualizations and Dashboards including the Medicare Part D Dashboard, NADAC Drug Pricing Dashboard, and Brand Drug List Price Change Box Score that aggregate public drug pricing data; (2) Original Research Publications analyzing PBM practices, supply chain dynamics, and pharmaceutical market distortions; (3) News and Podcast content covering current drug pricing developments; and (4) Resource tools including a Drug Channel Contracts Database, Public Drug Pricing Data Sources repository, and Pharmacy Terms Glossary. The organization takes disparate drug pricing data sources scattered across government databases and stitches them together into accessible formats for public education and policy advocacy.

Differentiator

Problem solved

Functional benefit

Products and services

• Medicare Part D Dashboard Interactive dashboard displaying Medicare Part D drug pricing and spending data, providing insights into prescription drug costs across the Medicare program for public and policy audiences.
• NADAC Drug Pricing Dashboard Dashboard tracking National Average Drug Acquisition Cost (NADAC) prices, showing pharmacy acquisition costs for generic and brand drugs over time.
• Brand Drug List Price Change Box Score Tracking tool for annual brand drug list price changes, providing week-by-week drugmaker activity insights based on Wholesale Acquisition Cost (WAC) data.
• 46brooklyn Research Data Visualizations Interactive data visualizations that aggregate and display U.S. drug pricing data from multiple sources including Medicare, Medicaid, NADAC, and commercial markets to help the public understand drug supply chain pricing dynamics.
• Drug Channel Contracts Database Repository of publicly-available drug channel contracts sourced from the internet, showing PBM reimbursement terms and AWP-based payment structures.
• 46brooklyn Podcast (Exploring the Opaque World of Drug Pricing) Audio content discussing drug pricing topics, supply chain analysis, and interviews with industry experts.
• Pharmacy Terms Glossary Educational resource providing definitions for key pharmacy terms and acronyms such as AWP, WAC, NADAC, NDC, MAC, and other drug pricing terminology.
• Public Drug Pricing Data Sources Curated list of public drug pricing data sources used by 46brooklyn for research, including CMS Medicaid/Medicare data, NADAC, and other government datasets.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves8 records

Expansion highlights3 records

Broad incumbents

• Definitive Healthcare: A commercial healthcare commercial-intelligence platform providing data on providers, payers, and the pharmaceutical supply chain. Comparable as a broader incumbent delivering healthcare and drug-supply-chain analytics, though as a paid B2B product rather than free public research.
• Kaiser Family Foundation (KFF): A leading health-policy research nonprofit producing widely cited analyses of prescription drug pricing, Medicare Part D, and Medicaid drug spending. Comparable as a high-authority donor-funded nonprofit whose drug-pricing research 46brooklyn's audience also relies on.
• PhRMA: The pharmaceutical industry's principal trade association publishes extensive drug-pricing data, policy research, and lobbying materials. Comparable as a broad incumbent producing drug-pricing content and analysis, though from an industry-advocacy perspective rather than 46brooklyn's transparency-focused lens.
• IQVIA: A global healthcare data and analytics incumbent providing commercial pharma market access, pricing, and reimbursement intelligence. Comparable as a much larger established player operating broadly in pharmaceutical pricing and market-access analytics.
• AARP Public Policy Institute: Publishes influential research on prescription drug prices, PBM practices, and Medicare drug spending for an older-American audience and policymakers. Comparable as an established nonprofit producing drug-pricing research and advocacy aimed at media and legislators.

Emerging players

• DrugAbacus (Memorial Sloan Kettering): An interactive drug-pricing tool from MSK that visualizes U.S. drug list prices and value-based benchmarks. Comparable as a public-facing, data-driven drug-pricing transparency resource aimed at policymakers and the public.
• West Health Policy Center: A nonprofit policy organization focused on lowering prescription drug prices and improving healthcare affordability. Comparable as a mission-aligned nonprofit producing drug-pricing research, policy analysis, and transparency content for media and state/federal policymakers.

Direct peers

• Patients For Affordable Drugs Now: A patient-advocacy nonprofit focused on lowering U.S. prescription drug prices, frequently citing and publishing drug-pricing data. Highly comparable as a mission-aligned, donation-funded nonprofit producing drug-pricing transparency content for media and policymakers.
• Drug Channels Institute: Adam Fein's research and advisory firm publishes deep analysis of U.S. drug pricing, PBMs, pharmacy economics, and the drug supply chain — the closest direct analog to 46brooklyn's research output and target audience of payers, manufacturers, and policymakers.
• 3 Axis Advisors: A drug-pricing and 340B consulting firm founded by Antonio Ciaccia after his earlier work analyzing state Medicaid drug spend — directly comparable in subject matter (340B, Medicaid, PBM) and overlapping in personnel and methodology with 46brooklyn.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/46brooklyn-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 46brooklyn Research